{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T15:35:31Z","timestamp":1793115331447,"version":"4.5.0"},"reference-count":111,"publisher":"American Society of Hematology","issue":"20","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,10,27]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Multiple myeloma (MM) accounts for \u223c12% of all hematologic malignancies and remains incurable despite therapeutic advances. Targeting tumor-associated antigens (TAAs) and tumor-specific neoantigens presented on HLA molecules by vaccination or T-cell receptor (TCR)\u2013redirected T cells offers a promising novel immunotherapeutic strategy. However, knowledge of targetable tumor antigens, especially neoantigens, is limited. We applied a mass spectrometry\u2013based immunopeptidomics approach on primary MM samples (n = 8) and MM cell lines (n = 3), integrating whole-exome and RNA sequencing to comprehensively characterize the MM immunopeptidome and systematically search for TAAs and neoantigens. Using our approach, we detected cancer-associated phosphopeptide HLA ligands as well as multiple cancer testis antigen\u2013derived HLA peptides, some shared between tumor samples. Proteogenomic analysis revealed primarily personalized patient-specific immunoglobulin-derived neoantigens generated by variable diversity joining recombination and somatic hypermutation, which were present in all samples. Three patients showed clustering of related major histocompatibility complex class II peptide ligands within the hypermutated region. In addition, we identified non\u2013immunoglobulin-derived neoantigens in both primary MM samples and cell lines. Approximately 30% of the cell line-derived peptides elicited CD8+ T-cell responses in allogeneic HLA-matched healthy donor peripheral blood mononuclear cells (PBMCs). In contrast, none of the patient-derived neoantigens were immunogenic in autologous PBMCs or tumor-infiltrating lymphocytes, reflecting severe immune dysfunction. This study provides, to our knowledge, the first proteogenomic-based identification of neoantigens in MM, extends the observation of presented immunoglobulin-derived neoantigens from B-cell lymphoma to MM, and highlights both actionable antigens and barriers to effective TCR-based immunotherapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2026019671","type":"journal-article","created":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T01:28:57Z","timestamp":1784770137000},"page":"7098-7114","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":0,"title":["Proteomic and proteogenomic identification of targetable T-cell antigens in multiple myeloma"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-6771-3005","authenticated-orcid":false,"given":"Gabriela","family":"Zuleger","sequence":"first","affiliation":[{"name":"1Medical Department III, School of Medicine and Health, TUM University Hospital, Technical University of Munich, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2141-6745","authenticated-orcid":false,"given":"Niklas","family":"de Andrade Kr\u00e4tzig","sequence":"additional","affiliation":[{"name":"2Institute of Molecular Oncology and Functional Genomics, School of Medicine and Health, Technical University of Munich, Munich, Germany"},{"name":"3Center for translational Cancer Research, School of Medicine and Health, Technical University of Munich, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2857-0841","authenticated-orcid":false,"given":"Piero","family":"Giansanti","sequence":"additional","affiliation":[{"name":"4Bavarian Center for Biomolecular Mass Spectrometry at TUM University Hospital, School of Medicine and Health, Technical University of Munich, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikos","family":"Darzentas","sequence":"additional","affiliation":[{"name":"5Medical Department II, Hematology and Oncology, University Hospital Schleswig-Holstein, Kiel, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5297-8356","authenticated-orcid":false,"given":"Mariagiovanna","family":"Barresi","sequence":"additional","affiliation":[{"name":"1Medical Department III, School of Medicine and Health, TUM University Hospital, Technical University of Munich, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-3603-6761","authenticated-orcid":false,"given":"Antonia","family":"Teske","sequence":"additional","affiliation":[{"name":"1Medical Department III, School of Medicine and Health, TUM University Hospital, Technical University of Munich, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5889-994X","authenticated-orcid":false,"given":"Riccardo","family":"Trozzo","sequence":"additional","affiliation":[{"name":"2Institute of Molecular Oncology and Functional Genomics, School of Medicine and Health, Technical University of Munich, Munich, Germany"},{"name":"3Center for translational Cancer Research, School of Medicine and Health, Technical University of Munich, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-4058-1348","authenticated-orcid":false,"given":"Sarah","family":"Lutzenberger","sequence":"additional","affiliation":[{"name":"1Medical Department III, School of Medicine and Health, TUM University Hospital, Technical University of Munich, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3008-3268","authenticated-orcid":false,"given":"Stefan","family":"Forster","sequence":"additional","affiliation":[{"name":"6Institute of Pathology, School of Medicine and Health, Technical University of Munich, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-7987-8990","authenticated-orcid":false,"given":"Alice","family":"Descoeudres","sequence":"additional","affiliation":[{"name":"7Gene Center, Ludwig Maximilian University of Munich, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur","family":"Wagner","sequence":"additional","affiliation":[{"name":"8Department for Neurosurgery, TUM University Hospital, Technical University of Munich, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanno S.","family":"Meyer","sequence":"additional","affiliation":[{"name":"8Department for Neurosurgery, TUM University Hospital, Technical University of Munich, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Hammel","sequence":"additional","affiliation":[{"name":"9Institute for Medical Microbiology, Immunology and Hygiene, School of Medicine and Health, Technical University of Munich, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7697-6374","authenticated-orcid":false,"given":"Chien-Yun","family":"Lee","sequence":"additional","affiliation":[{"name":"10Institute of Proteomics and Bioanalytics, Technical University of Munich, Freising, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4600-1394","authenticated-orcid":false,"given":"Michael","family":"Hiltensperger","sequence":"additional","affiliation":[{"name":"1Medical Department III, School of Medicine and Health, TUM University Hospital, Technical University of Munich, Munich, Germany"},{"name":"11German Cancer Consortium of Translational Cancer Research, Munich and German Cancer Research Center, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8713-093X","authenticated-orcid":false,"given":"Dirk H.","family":"Busch","sequence":"additional","affiliation":[{"name":"9Institute for Medical Microbiology, Immunology and Hygiene, School of Medicine and Health, Technical University of Munich, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6486-7955","authenticated-orcid":false,"given":"Bernhard","family":"Meyer","sequence":"additional","affiliation":[{"name":"8Department for Neurosurgery, TUM University Hospital, Technical University of Munich, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4719-8010","authenticated-orcid":false,"given":"Stefan","family":"Canzar","sequence":"additional","affiliation":[{"name":"12Faculty of Informatics and Data Science, University of Regensburg, Regensburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1531-0517","authenticated-orcid":false,"given":"Judith S.","family":"Hecker","sequence":"additional","affiliation":[{"name":"1Medical Department III, School of Medicine and Health, TUM University Hospital, Technical University of Munich, Munich, Germany"},{"name":"3Center for translational Cancer Research, School of Medicine and Health, Technical University of Munich, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5514-5010","authenticated-orcid":false,"given":"Monika","family":"Br\u00fcggemann","sequence":"additional","affiliation":[{"name":"5Medical Department II, Hematology and Oncology, University Hospital Schleswig-Holstein, Kiel, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland","family":"Rad","sequence":"additional","affiliation":[{"name":"2Institute of Molecular Oncology and Functional Genomics, School of Medicine and Health, Technical University of Munich, Munich, Germany"},{"name":"3Center for translational Cancer Research, School of Medicine and Health, Technical University of Munich, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9640-3741","authenticated-orcid":false,"given":"Eva","family":"Br\u00e4unlein","sequence":"additional","affiliation":[{"name":"1Medical Department III, School of Medicine and Health, TUM University Hospital, Technical University of Munich, Munich, Germany"},{"name":"11German Cancer Consortium of Translational Cancer Research, Munich and German Cancer Research Center, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4752-0543","authenticated-orcid":false,"given":"Angela M.","family":"Krackhardt","sequence":"additional","affiliation":[{"name":"1Medical Department III, School of Medicine and Health, TUM University Hospital, Technical University of Munich, Munich, Germany"},{"name":"3Center for translational Cancer Research, School of Medicine and Health, Technical University of Munich, Munich, Germany"},{"name":"11German Cancer Consortium of Translational Cancer Research, Munich and German Cancer Research Center, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,10,16]]},"reference":[{"issue":"3","key":"2026102711125364300_bib1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"2026102711125364300_bib2","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/s41408-023-00853-3","article-title":"Global burden of hematologic malignancies and evolution patterns over the past 30 years","volume":"13","author":"Zhang","year":"2023","journal-title":"Blood Cancer J"},{"issue":"2","key":"2026102711125364300_bib3","doi-asserted-by":"crossref","first-page":"360","DOI":"10.3324\/haematol.2013.094409","article-title":"Soft-tissue extramedullary multiple myeloma prognosis is significantly worse in comparison to bone-related extramedullary relapse","volume":"99","author":"Pour","year":"2014","journal-title":"Haematologica"},{"issue":"1","key":"2026102711125364300_bib4","doi-asserted-by":"crossref","first-page":"193","DOI":"10.3324\/haematol.2019.219139","article-title":"Outcome of paraosseous extra-medullary disease in newly diagnosed multiple myeloma patients treated with new drugs","volume":"105","author":"Montefusco","year":"2020","journal-title":"Haematologica"},{"issue":"24","key":"2026102711125364300_bib5","doi-asserted-by":"crossref","first-page":"13931","DOI":"10.1073\/pnas.93.24.13931","article-title":"Promiscuous translocations into immunoglobulin heavy chain switch regions in multiple myeloma","volume":"93","author":"Bergsagel","year":"1996","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"2026102711125364300_bib6","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1182\/blood.V88.2.674.bloodjournal882674","article-title":"Dysregulation of cyclin D1 by translocation into an IgH gamma switch region in two multiple myeloma cell lines","volume":"88","author":"Chesi","year":"1996","journal-title":"Blood"},{"issue":"2","key":"2026102711125364300_bib7","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S1535-6108(04)00019-4","article-title":"Overexpression of c-maf is a frequent oncogenic event in multiple myeloma that promotes proliferation and pathological interactions with bone marrow stroma","volume":"5","author":"Hurt","year":"2004","journal-title":"Cancer Cell"},{"key":"2026102711125364300_bib8","doi-asserted-by":"crossref","first-page":"101168","DOI":"10.1016\/j.blre.2024.101168","article-title":"Chromosomal defects in multiple myeloma","volume":"64","author":"Clarke","year":"2024","journal-title":"Blood Rev"},{"issue":"7339","key":"2026102711125364300_bib9","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/nature09837","article-title":"Initial genome sequencing and analysis of multiple myeloma","volume":"471","author":"Chapman","year":"2011","journal-title":"Nature"},{"issue":"33","key":"2026102711125364300_bib10","doi-asserted-by":"crossref","first-page":"3911","DOI":"10.1200\/JCO.2014.59.1503","article-title":"Mutational spectrum, copy number changes, and outcome: results of a sequencing study of patients with newly diagnosed myeloma","volume":"33","author":"Walker","year":"2015","journal-title":"J Clin Oncol"},{"issue":"5","key":"2026102711125364300_bib11","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41408-020-0311-8","article-title":"Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT)","volume":"10","author":"Durie","year":"2020","journal-title":"Blood Cancer J"},{"issue":"4","key":"2026102711125364300_bib12","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1038\/s41375-024-02505-2","article-title":"Daratumumab\/lenalidomide\/dexamethasone in transplant-ineligible newly diagnosed myeloma: MAIA long-term outcomes","volume":"39","author":"Facon","year":"2025","journal-title":"Leukemia"},{"issue":"8","key":"2026102711125364300_bib13","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/S1470-2045(24)00282-1","article-title":"Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial","volume":"25","author":"Moreau","year":"2024","journal-title":"Lancet Oncol"},{"issue":"10","key":"2026102711125364300_bib14","doi-asserted-by":"crossref","first-page":"e825","DOI":"10.1016\/S2352-3026(23)00217-X","article-title":"Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial","volume":"10","author":"Voorhees","year":"2023","journal-title":"Lancet Haematol"},{"issue":"14","key":"2026102711125364300_bib15","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1056\/NEJMoa1611750","article-title":"Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma","volume":"376","author":"Attal","year":"2017","journal-title":"N Engl J Med"},{"issue":"2","key":"2026102711125364300_bib16","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1056\/NEJMoa2204925","article-title":"Triplet therapy, transplantation, and maintenance until progression in myeloma","volume":"387","author":"Richardson","year":"2022","journal-title":"N Engl J Med"},{"issue":"8","key":"2026102711125364300_bib17","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med"},{"issue":"10297","key":"2026102711125364300_bib18","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"issue":"18","key":"2026102711125364300_bib19","first-page":"1722","article-title":"Teclistamab in relapsed or refractory multiple myeloma. Reply","volume":"387","author":"Moreau","year":"2022","journal-title":"N Engl J Med"},{"issue":"9","key":"2026102711125364300_bib20","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","article-title":"Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results","volume":"29","author":"Lesokhin","year":"2023","journal-title":"Nat Med"},{"issue":"24","key":"2026102711125364300_bib21","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","article-title":"Talquetamab, a T-cell-redirecting GPRC5D bispecific antibody for multiple myeloma","volume":"387","author":"Chari","year":"2022","journal-title":"N Engl J Med"},{"issue":"5","key":"2026102711125364300_bib22","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/s41568-023-00560-y","article-title":"Dynamics and specificities of T cells in cancer immunotherapy","volume":"23","author":"Oliveira","year":"2023","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"2026102711125364300_bib23","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1056\/NEJMra1706169","article-title":"Chimeric antigen receptor therapy","volume":"379","author":"June","year":"2018","journal-title":"N Engl J Med"},{"issue":"6230","key":"2026102711125364300_bib24","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1126\/science.aaa4971","article-title":"Neoantigens in cancer immunotherapy","volume":"348","author":"Schumacher","year":"2015","journal-title":"Science"},{"issue":"10435","key":"2026102711125364300_bib25","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1016\/S0140-6736(24)00319-2","article-title":"Afamitresgene autoleucel for advanced synovial sarcoma and myxoid round cell liposarcoma (SPEARHEAD-1): an international, open-label, phase 2 trial","volume":"403","author":"D'Angelo","year":"2024","journal-title":"Lancet"},{"issue":"7953","key":"2026102711125364300_bib26","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1038\/s41586-022-05531-1","article-title":"Non-viral precision T cell receptor replacement for personalized cell therapy","volume":"615","author":"Foy","year":"2023","journal-title":"Nature"},{"issue":"9","key":"2026102711125364300_bib27","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1038\/s41591-024-03109-0","article-title":"Adoptive transfer of personalized neoantigen-reactive TCR-transduced T cells in metastatic colorectal cancer: phase 2 trial interim results","volume":"30","author":"Parkhurst","year":"2024","journal-title":"Nat Med"},{"issue":"3","key":"2026102711125364300_bib28","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1038\/s41591-024-03418-4","article-title":"Personalized, autologous neoantigen-specific T cell therapy in metastatic melanoma: a phase 1 trial","volume":"31","author":"Borgers","year":"2025","journal-title":"Nat Med"},{"issue":"7","key":"2026102711125364300_bib29","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/s41568-025-00820-z","article-title":"Recent advances in therapeutic cancer vaccines","volume":"25","author":"Zaidi","year":"2025","journal-title":"Nat Rev Cancer"},{"issue":"4","key":"2026102711125364300_bib30","doi-asserted-by":"crossref","first-page":"e010673","DOI":"10.1136\/jitc-2024-010673","article-title":"Immunopeptidomics identified antigens for mRNA-lipid nanoparticle vaccines with alpha-galactosylceramide in multiple myeloma therapy","volume":"13","author":"Van der Vreken","year":"2025","journal-title":"J Immunother Cancer"},{"issue":"9","key":"2026102711125364300_bib31","doi-asserted-by":"crossref","first-page":"e612","DOI":"10.1038\/bcj.2017.94","article-title":"High somatic mutation and neoantigen burden are correlated with decreased progression-free survival in multiple myeloma","volume":"7","author":"Miller","year":"2017","journal-title":"Blood Cancer J"},{"issue":"2","key":"2026102711125364300_bib32","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1158\/1078-0432.CCR-19-2309","article-title":"Mutation-derived neoantigen-specific T-cell responses in multiple myeloma","volume":"26","author":"Perumal","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"42","key":"2026102711125364300_bib33","doi-asserted-by":"crossref","first-page":"6130","DOI":"10.1038\/s41388-021-02005-y","article-title":"Intron retention-induced neoantigen load correlates with unfavorable prognosis in multiple myeloma","volume":"40","author":"Dong","year":"2021","journal-title":"Oncogene"},{"key":"2026102711125364300_bib34","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.omtn.2022.07.006","article-title":"NAIRscore as a biomarker for the quality of immune response to neoantigens is related with an increased overall survival in multiple myeloma","volume":"29","author":"Jian","year":"2022","journal-title":"Mol Ther Nucleic Acids"},{"key":"2026102711125364300_bib35","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.omtm.2023.05.014","article-title":"Detection of mutant antigen-specific T cell receptors against multiple myeloma for T cell engineering","volume":"29","author":"Okada","year":"2023","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"12","key":"2026102711125364300_bib36","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1158\/1535-7163.MCT-23-0931","article-title":"Immunoproteasome activation expands the MHC class I immunopeptidome, unmasks neoantigens, and enhances T-cell anti-myeloma activity","volume":"23","author":"Rana","year":"2024","journal-title":"Mol Cancer Ther"},{"issue":"4","key":"2026102711125364300_bib37","doi-asserted-by":"crossref","first-page":"440","DOI":"10.4149\/neo_2012_057","article-title":"Efficacy and safety of Id-protein-loaded dendritic cell vaccine in patients with multiple myeloma--phase II study results","volume":"59","author":"Zahradova","year":"2012","journal-title":"Neoplasma"},{"issue":"5","key":"2026102711125364300_bib38","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1158\/1078-0432.CCR-06-1603","article-title":"Long-term idiotype vaccination combined with interleukin-12 (IL-12), or IL-12 and granulocyte macrophage colony-stimulating factor, in early-stage multiple myeloma patients","volume":"13","author":"Hansson","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"3","key":"2026102711125364300_bib39","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1111\/j.1365-2141.2007.06832.x","article-title":"Phase I\/II clinical trial of sequential subcutaneous and intravenous delivery of dendritic cell vaccination for refractory multiple myeloma using patient-specific tumour idiotype protein or idiotype (VDJ)-derived class I-restricted peptides","volume":"139","author":"Curti","year":"2007","journal-title":"Br J Haematol"},{"issue":"9","key":"2026102711125364300_bib40","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1182\/blood.2020008493","article-title":"A randomized phase 2 trial of idiotype vaccination and adoptive autologous T-cell transfer in patients with multiple myeloma","volume":"139","author":"Qazilbash","year":"2022","journal-title":"Blood"},{"issue":"7647","key":"2026102711125364300_bib41","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1038\/nature21433","article-title":"Antigen presentation profiling reveals recognition of lymphoma immunoglobulin neoantigens","volume":"543","author":"Khodadoust","year":"2017","journal-title":"Nature"},{"issue":"8","key":"2026102711125364300_bib42","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1182\/blood-2018-06-845156","article-title":"B-cell lymphomas present immunoglobulin neoantigens","volume":"133","author":"Khodadoust","year":"2019","journal-title":"Blood"},{"issue":"1","key":"2026102711125364300_bib43","doi-asserted-by":"crossref","first-page":"4632","DOI":"10.1038\/s41467-023-39570-7","article-title":"Proteogenomic analysis reveals RNA as a source for tumor-agnostic neoantigen identification","volume":"14","author":"Tretter","year":"2023","journal-title":"Nat Commun"},{"key":"2026102711125364300_bib44","doi-asserted-by":"crossref","first-page":"13404","DOI":"10.1038\/ncomms13404","article-title":"Direct identification of clinically relevant neoepitopes presented on native human melanoma tissue by mass spectrometry","volume":"7","author":"Bassani-Sternberg","year":"2016","journal-title":"Nat Commun"},{"issue":"2","key":"2026102711125364300_bib45","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1038\/s41596-019-0234-7","article-title":"Analysis pipelines for cancer genome sequencing in mice","volume":"15","author":"Lange","year":"2020","journal-title":"Nat Protoc"},{"issue":"8","key":"2026102711125364300_bib46","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/s41592-018-0051-x","article-title":"Strelka2: fast and accurate calling of germline and somatic variants","volume":"15","author":"Kim","year":"2018","journal-title":"Nat Methods"},{"issue":"7809","key":"2026102711125364300_bib47","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1038\/s41586-020-2308-7","article-title":"The mutational constraint spectrum quantified from variation in 141,456 humans","volume":"581","author":"Karczewski","year":"2020","journal-title":"Nature"},{"issue":"8","key":"2026102711125364300_bib48","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1101\/gr.9.8.677","article-title":"dbSNP-database for single nucleotide polymorphisms and other classes of minor genetic variation","volume":"9","author":"Sherry","year":"1999","journal-title":"Genome Res"},{"key":"2026102711125364300_bib49","unstructured":"NikdAK\/VCFtranslate\n          . Version 1.0.0. 2023. Accessed 3 August 2026. https:\/\/zenodo.org\/records\/7965941."},{"issue":"16","key":"2026102711125364300_bib50","first-page":"3188","article-title":"Validation of the EuroClonality-NGS DNA capture panel as an integrated genomic tool for lymphoproliferative disorders","volume":"5","author":"Stewart","year":"2021","journal-title":"Blood Adv"},{"issue":"3","key":"2026102711125364300_bib51","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1038\/s41375-021-01154-z","article-title":"Potential and pitfalls of whole transcriptome-based immunogenetic marker identification in acute lymphoblastic leukemia; a EuroMRD and EuroClonality-NGS Working Group study","volume":"35","author":"van der Velden","year":"2021","journal-title":"Leukemia"},{"key":"2026102711125364300_bib52","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/978-1-0716-2115-8_4","article-title":"Immunoglobulin\/T-cell receptor gene rearrangement analysis using RNA-seq","volume":"2453","author":"van der Velden","year":"2022","journal-title":"Methods Mol Biol"},{"issue":"30","key":"2026102711125364300_bib53","doi-asserted-by":"crossref","first-page":"8059","DOI":"10.1073\/pnas.1707945114","article-title":"Fast and accurate HLA typing from short-read next-generation sequence data with xHLA","volume":"114","author":"Xie","year":"2017","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"14","key":"2026102711125364300_bib54","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1093\/bioinformatics\/btp324","article-title":"Fast and accurate short read alignment with Burrows-Wheeler transform","volume":"25","author":"Li","year":"2009","journal-title":"Bioinformatics"},{"issue":"23","key":"2026102711125364300_bib55","doi-asserted-by":"crossref","first-page":"3310","DOI":"10.1093\/bioinformatics\/btu548","article-title":"OptiType: precision HLA typing from next-generation sequencing data","volume":"30","author":"Szolek","year":"2014","journal-title":"Bioinformatics"},{"issue":"1","key":"2026102711125364300_bib56","doi-asserted-by":"crossref","first-page":"10520","DOI":"10.1038\/s41467-024-53911-0","article-title":"High-resolution profile of neoantigen-specific TCR activation links moderate stimulation to increased resilience of engineered TCR-T cells","volume":"15","author":"Fuchsl","year":"2024","journal-title":"Nat Commun"},{"issue":"5","key":"2026102711125364300_bib57","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/nmeth.4256","article-title":"MSFragger: ultrafast and comprehensive peptide identification in mass spectrometry-based proteomics","volume":"14","author":"Kong","year":"2017","journal-title":"Nat Methods"},{"issue":"12","key":"2026102711125364300_bib58","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1038\/nbt.1511","article-title":"MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification","volume":"26","author":"Cox","year":"2008","journal-title":"Nat Biotechnol"},{"issue":"1","key":"2026102711125364300_bib59","doi-asserted-by":"crossref","first-page":"3346","DOI":"10.1038\/s41467-021-23713-9","article-title":"Deep learning boosts sensitivity of mass spectrometry-based immunopeptidomics","volume":"12","author":"Wilhelm","year":"2021","journal-title":"Nat Commun"},{"issue":"W1","key":"2026102711125364300_bib60","doi-asserted-by":"crossref","first-page":"W449","DOI":"10.1093\/nar\/gkaa379","article-title":"NetMHCpan-4.1 and NetMHCIIpan-4.0: improved predictions of MHC antigen presentation by concurrent motif deconvolution and integration of MS MHC eluted ligand data","volume":"48","author":"Reynisson","year":"2020","journal-title":"Nucleic Acids Res"},{"issue":"database issue","key":"2026102711125364300_bib61","doi-asserted-by":"crossref","first-page":"D816","DOI":"10.1093\/nar\/gkn673","article-title":"CTdatabase: a knowledge-base of high-throughput and curated data on cancer-testis antigens","volume":"37","author":"Almeida","year":"2009","journal-title":"Nucleic Acids Res"},{"issue":"8","key":"2026102711125364300_bib62","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1182\/blood-2010-12-326231","article-title":"acDCs enhance human antigen-specific T-cell responses","volume":"118","author":"Martinuzzi","year":"2011","journal-title":"Blood"},{"issue":"40","key":"2026102711125364300_bib63","doi-asserted-by":"crossref","first-page":"14889","DOI":"10.1073\/pnas.0604045103","article-title":"Identification of class I MHC-associated phosphopeptides as targets for cancer immunotherapy","volume":"103","author":"Zarling","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"11","key":"2026102711125364300_bib64","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1038\/ni.1660","article-title":"Phosphorylation-dependent interaction between antigenic peptides and MHC class I: a molecular basis for the presentation of transformed self","volume":"9","author":"Mohammed","year":"2008","journal-title":"Nat Immunol"},{"issue":"203","key":"2026102711125364300_bib65","doi-asserted-by":"crossref","first-page":"203ra125","DOI":"10.1126\/scitranslmed.3006061","article-title":"MHC class I-associated phosphopeptides are the targets of memory-like immunity in leukemia","volume":"5","author":"Cobbold","year":"2013","journal-title":"Sci Transl Med"},{"key":"2026102711125364300_bib66","doi-asserted-by":"crossref","first-page":"723566","DOI":"10.3389\/fimmu.2021.723566","article-title":"Tumor infiltrating lymphocytes target HLA-I phosphopeptides derived from cancer signaling in colorectal cancer","volume":"12","author":"Penny","year":"2021","journal-title":"Front Immunol"},{"issue":"20","key":"2026102711125364300_bib67","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1182\/blood.2024024590","article-title":"Spatial transcriptomics reveals profound subclonal heterogeneity and T-cell dysfunction in extramedullary myeloma","volume":"144","author":"John","year":"2024","journal-title":"Blood"},{"issue":"10","key":"2026102711125364300_bib68","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1182\/blood-2015-04-640532","article-title":"The antigenic landscape of multiple myeloma: mass spectrometry (re)defines targets for T-cell-based immunotherapy","volume":"126","author":"Walz","year":"2015","journal-title":"Blood"},{"issue":"9","key":"2026102711125364300_bib69","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1074\/mcp.R113.027797","article-title":"Combining results of multiple search engines in proteomics","volume":"12","author":"Shteynberg","year":"2013","journal-title":"Mol Cell Proteomics"},{"issue":"47","key":"2026102711125364300_bib70","doi-asserted-by":"crossref","first-page":"eadj6367","DOI":"10.1126\/sciadv.adj6367","article-title":"Accurate prediction of HLA class II antigen presentation across all loci using tailored data acquisition and refined machine learning","volume":"9","author":"Nilsson","year":"2023","journal-title":"Sci Adv"},{"issue":"4","key":"2026102711125364300_bib71","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/nri3818","article-title":"The ins and outs of MHC class II-mediated antigen processing and presentation","volume":"15","author":"Roche","year":"2015","journal-title":"Nat Rev Immunol"},{"issue":"11","key":"2026102711125364300_bib72","doi-asserted-by":"crossref","first-page":"2923","DOI":"10.1016\/j.molimm.2007.01.009","article-title":"MHC class II transactivator (CIITA) expression is upregulated in multiple myeloma cells by IFN-gamma","volume":"44","author":"Zhao","year":"2007","journal-title":"Mol Immunol"},{"issue":"9","key":"2026102711125364300_bib73","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1038\/s41375-018-0062-8","article-title":"Histone deacetylase (HDAC) inhibitor ACY241 enhances anti-tumor activities of antigen-specific central memory cytotoxic T lymphocytes against multiple myeloma and solid tumors","volume":"32","author":"Bae","year":"2018","journal-title":"Leukemia"},{"issue":"1","key":"2026102711125364300_bib74","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1186\/s12885-024-12148-2","article-title":"Targeting PCSK9 to upregulate MHC-II on the surface of tumor cells in tumor immunotherapy","volume":"24","author":"Wang","year":"2024","journal-title":"BMC Cancer"},{"issue":"1","key":"2026102711125364300_bib75","doi-asserted-by":"crossref","first-page":"244","DOI":"10.3324\/haematol.2024.286124","article-title":"A phase I study of MAGE-A1-targeted T1367 T-cell receptorbased cell therapy in patients with advanced multiple myeloma","volume":"110","author":"Kruger","year":"2025","journal-title":"Haematologica"},{"issue":"6","key":"2026102711125364300_bib76","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1111\/j.1365-2141.2012.09111.x","article-title":"A novel immunogenic CS1-specific peptide inducing antigen-specific cytotoxic T lymphocytes targeting multiple myeloma","volume":"157","author":"Bae","year":"2012","journal-title":"Br J Haematol"},{"issue":"5","key":"2026102711125364300_bib77","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1182\/blood-2007-03-082529","article-title":"Dickkopf-1 (DKK1) is a widely expressed and potent tumor-associated antigen in multiple myeloma","volume":"110","author":"Qian","year":"2007","journal-title":"Blood"},{"issue":"10","key":"2026102711125364300_bib78","doi-asserted-by":"crossref","first-page":"3538","DOI":"10.1182\/blood-2005-04-1438","article-title":"Induction of HM1.24 peptide-specific cytotoxic T lymphocytes by using peripheral-blood stem-cell harvests in patients with multiple myeloma","volume":"106","author":"Jalili","year":"2005","journal-title":"Blood"},{"issue":"13","key":"2026102711125364300_bib79","doi-asserted-by":"crossref","first-page":"4217","DOI":"10.1182\/blood-2005-02-0563","article-title":"CD8+ T cells specific for cancer germline gene antigens are found in many patients with multiple myeloma, and their frequency correlates with disease burden","volume":"106","author":"Goodyear","year":"2005","journal-title":"Blood"},{"issue":"10","key":"2026102711125364300_bib80","doi-asserted-by":"crossref","first-page":"3939","DOI":"10.1182\/blood-2004-09-3707","article-title":"NY-ESO-1 is highly expressed in poor-prognosis multiple myeloma and induces spontaneous humoral and cellular immune responses","volume":"105","author":"van Rhee","year":"2005","journal-title":"Blood"},{"issue":"2","key":"2026102711125364300_bib81","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41408-020-0288-3","article-title":"Mass spectrometry-based identification of a B-cell maturation antigen-derived T-cell epitope for antigen-specific immunotherapy of multiple myeloma","volume":"10","author":"Bilich","year":"2020","journal-title":"Blood Cancer J"},{"issue":"8","key":"2026102711125364300_bib82","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1038\/s43018-024-00784-3","article-title":"The proteogenomic landscape of multiple myeloma reveals insights into disease biology and therapeutic opportunities","volume":"5","author":"Ramberger","year":"2024","journal-title":"Nat Cancer"},{"issue":"9","key":"2026102711125364300_bib83","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1182\/blood.V80.9.2326.2326","article-title":"Evidence that multiple myeloma Ig heavy chain VDJ genes contain somatic mutations but show no intraclonal variation","volume":"80","author":"Bakkus","year":"1992","journal-title":"Blood"},{"issue":"9","key":"2026102711125364300_bib84","doi-asserted-by":"crossref","first-page":"3112","DOI":"10.1182\/blood-2007-02-069625","article-title":"Immunoglobulin gene rearrangements and the pathogenesis of multiple myeloma","volume":"110","author":"Gonzalez","year":"2007","journal-title":"Blood"},{"issue":"2","key":"2026102711125364300_bib85","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/s41408-020-0283-8","article-title":"Molecular profiling of immunoglobulin heavy-chain gene rearrangements unveils new potential prognostic markers for multiple myeloma patients","volume":"10","author":"Medina","year":"2020","journal-title":"Blood Cancer J"},{"issue":"1","key":"2026102711125364300_bib86","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1073\/pnas.86.1.282","article-title":"B-lymphoma cells process and present their endogenous immunoglobulin to major histocompatibility complex-restricted T cells","volume":"86","author":"Weiss","year":"1989","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"2026102711125364300_bib87","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/76243","article-title":"Immunoglobulin framework-derived peptides function as cytotoxic T-cell epitopes commonly expressed in B-cell malignancies","volume":"6","author":"Trojan","year":"2000","journal-title":"Nat Med"},{"issue":"8956","key":"2026102711125364300_bib88","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/S0140-6736(95)90757-2","article-title":"Transfer of myeloma idiotype-specific immunity from an actively immunised marrow donor","volume":"345","author":"Kwak","year":"1995","journal-title":"Lancet"},{"issue":"4","key":"2026102711125364300_bib89","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/0092-8674(91)90506-T","article-title":"MHC class II-restricted presentation of intracellular antigen","volume":"64","author":"Weiss","year":"1991","journal-title":"Cell"},{"issue":"2","key":"2026102711125364300_bib90","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1097\/CJI.0b013e3182829903","article-title":"Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy","volume":"36","author":"Morgan","year":"2013","journal-title":"J Immunother"},{"issue":"197","key":"2026102711125364300_bib91","doi-asserted-by":"crossref","first-page":"197ra103","DOI":"10.1126\/scitranslmed.3006034","article-title":"Identification of a Titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells","volume":"5","author":"Cameron","year":"2013","journal-title":"Sci Transl Med"},{"issue":"1","key":"2026102711125364300_bib92","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ccell.2022.10.013","article-title":"Challenges in neoantigen-directed therapeutics","volume":"41","author":"Lybaert","year":"2023","journal-title":"Cancer Cell"},{"issue":"1","key":"2026102711125364300_bib93","doi-asserted-by":"crossref","first-page":"7269","DOI":"10.1038\/s41467-025-62647-4","article-title":"Sensitive neoantigen discovery by real-time mutanome-guided immunopeptidomics","volume":"16","author":"Shapiro","year":"2025","journal-title":"Nat Commun"},{"issue":"8","key":"2026102711125364300_bib94","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1038\/s41587-024-02420-y","article-title":"A comprehensive proteogenomic pipeline for neoantigen discovery to advance personalized cancer immunotherapy","volume":"43","author":"Huber","year":"2025","journal-title":"Nat Biotechnol"},{"issue":"11","key":"2026102711125364300_bib95","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1038\/nbt.4239","article-title":"Intron retention is a source of neoepitopes in cancer","volume":"36","author":"Smart","year":"2018","journal-title":"Nat Biotechnol"},{"key":"2026102711125364300_bib96","doi-asserted-by":"crossref","first-page":"593989","DOI":"10.3389\/fonc.2020.593989","article-title":"Systematically characterizing A-to-I RNA editing neoantigens in cancer","volume":"10","author":"Zhou","year":"2020","journal-title":"Front Oncol"},{"issue":"1","key":"2026102711125364300_bib97","doi-asserted-by":"crossref","first-page":"3919","DOI":"10.1038\/s41467-018-06405-9","article-title":"RNA editing derived epitopes function as cancer antigens to elicit immune responses","volume":"9","author":"Zhang","year":"2018","journal-title":"Nat Commun"},{"key":"2026102711125364300_bib98","doi-asserted-by":"publisher","DOI":"10.1101\/2023.10.19.563178","article-title":"Tumor-wide RNA splicing aberrations generate immunogenic public neoantigens","author":"Kwok","year":"20  2023","journal-title":"bioRxiv"},{"issue":"24","key":"2026102711125364300_bib99","doi-asserted-by":"crossref","first-page":"21651","DOI":"10.1002\/cam4.6721","article-title":"The loss of neoantigens is an important reason for immune escape in multiple myeloma patients with high intratumor heterogeneity","volume":"12","author":"Wang","year":"2023","journal-title":"Cancer Med"},{"issue":"4","key":"2026102711125364300_bib100","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/s41573-021-00387-y","article-title":"Identification of neoantigens for individualized therapeutic cancer vaccines","volume":"21","author":"Lang","year":"2022","journal-title":"Nat Rev Drug Discov"},{"issue":"17","key":"2026102711125364300_bib101","doi-asserted-by":"crossref","first-page":"10131","DOI":"10.3390\/ijms231710131","article-title":"Sources of cancer neoantigens beyond single-nucleotide variants","volume":"23","author":"Capietto","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"14","key":"2026102711125364300_bib102","doi-asserted-by":"crossref","first-page":"e129152","DOI":"10.1172\/jci.insight.129152","article-title":"Mass spectrometry driven exploration reveals nuances of neoepitope-driven tumor rejection","volume":"5","author":"Ebrahimi-Nik","year":"2019","journal-title":"JCI Insight"},{"issue":"1","key":"2026102711125364300_bib103","doi-asserted-by":"crossref","first-page":"79","DOI":"10.3324\/haematol.2012.067272","article-title":"Analysis of the immune system of multiple myeloma patients achieving long-term disease control by multidimensional flow cytometry","volume":"98","author":"Pessoa de Magalhaes","year":"2013","journal-title":"Haematologica"},{"issue":"6","key":"2026102711125364300_bib104","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1111\/j.1365-3083.2010.02463.x","article-title":"Increased level of both CD4+FOXP3+ regulatory T cells and CD14+HLA-DR(-)\/low myeloid-derived suppressor cells and decreased level of dendritic cells in patients with multiple myeloma","volume":"72","author":"Brimnes","year":"2010","journal-title":"Scand J Immunol"},{"issue":"1","key":"2026102711125364300_bib105","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1182\/blood.V100.1.230","article-title":"Dendritic cells are functionally defective in multiple myeloma: the role of interleukin-6","volume":"100","author":"Ratta","year":"2002","journal-title":"Blood"},{"issue":"1","key":"2026102711125364300_bib106","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/s13045-016-0345-3","article-title":"T cells in multiple myeloma display features of exhaustion and senescence at the tumor site","volume":"9","author":"Zelle-Rieser","year":"2016","journal-title":"J Hematol Oncol"},{"issue":"8","key":"2026102711125364300_bib107","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1038\/leu.2016.84","article-title":"Multiple myeloma causes clonal T-cell immunosenescence: identification of potential novel targets for promoting tumour immunity and implications for checkpoint blockade","volume":"30","author":"Suen","year":"2016","journal-title":"Leukemia"},{"key":"2026102711125364300_bib108","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2025031897","article-title":"TCR T cells targeting IgA- and IgG-expressing multiple myeloma","author":"Douvlataniotis","year":"2  2026","journal-title":"Blood"},{"issue":"22","key":"2026102711125364300_bib109","doi-asserted-by":"crossref","first-page":"3776","DOI":"10.3390\/cancers16223776","article-title":"Unlocking intracellular oncology targets: the unique role of antibody-based T-cell receptor mimic (TCRm) therapeutics in T-cell engagers (TCEs) and antibody-drug conjugates (ADCs)","volume":"16","author":"Molldrem","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"6758","key":"2026102711125364300_bib110","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1126\/science.adv3813","article-title":"De novo design and structure of a peptide-centric TCR mimic binding module","volume":"389","author":"Householder","year":"2025","journal-title":"Science"},{"key":"2026102711125364300_bib111","doi-asserted-by":"publisher","DOI":"10.64898\/2026.05.15.725176","article-title":"Engineering endogenous T cell receptors to recognize cancer neoantigens using a hybrid physics-AI approach","author":"Weber","year":"19  2026","journal-title":"bioRxiv"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/20\/7098\/2595365\/blooda_adv-2026-019671-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/20\/7098\/2595365\/blooda_adv-2026-019671-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T15:13:11Z","timestamp":1793113991000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/20\/7098\/569802\/Proteomic-and-proteogenomic-identification-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,16]]},"references-count":111,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2026,10,27]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2026019671","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,10,27]]},"published":{"date-parts":[[2026,10,16]]}}}